Evotec (EVT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Jun, 2026Executive summary
Annual Meeting scheduled for August 6, 2026, at the principal office in Boston, MA, for five Eaton Vance funds.
Main agenda is the election of Class II Trustees for each fund, with voting by shareholders of record as of June 2, 2026.
Proxy materials, including the proxy statement and shareholder reports, are available online and by request.
Shareholders are encouraged to vote by proxy even if not attending in person; proxies are revocable.
Voting matters and shareholder proposals
Election of Trustees is the sole proposal, with specific nominees for each fund and share class.
Shareholders may also act on any other matters properly brought before the meeting.
Shareholder proposals for the 2027 meeting must be submitted by February 23, 2027, for inclusion.
Board of directors and corporate governance
Each fund's board consists of nine noninterested Trustees, divided into three classes with staggered three-year terms.
Trustees have diverse backgrounds in investment management, academia, and corporate governance.
Board committees include Audit, Contract Review, Governance, Portfolio Management, Compliance, and Closed-End Fund Committees.
Board and committee meetings are held regularly, with all Trustees attending at least 75% of meetings in 2025.
Governance Committee considers diversity and overall board composition in nominating Trustees.
Latest events from Evotec
- Revenue and profitability declined sharply, with losses deepening and guidance lowered for 2026.EVT
Q2 2026 - Accelerating growth with innovation, cost savings, and a high-value asset pipeline.EVT
Company presentation - 2026 outlook cut as partnership delays weigh, but core business segments show strong momentum.EVT
Q2 2026 TU - Operational excellence, pipeline growth, and asset-light strategy drive sustainable value creation.EVT
Company presentation - Q1 2026 revenues fell to €156.6m as transformation and cost-saving measures advanced.EVT
Q1 2026 - Biologics growth, cost savings, and Horizon transformation drive high-end 2025 results.EVT
Q4 2025 - Biologics growth and €40m cost savings offset R&D decline, supporting 2024 guidance.EVT
Q3 2024 - Revenue up 2%, but losses deepened and restructuring accelerated in H1 2024.EVT
Q2 2024 - Revenue fell 4% but Biologics grew 10–11%, with guidance and cost savings reaffirmed.EVT
Q1 2025